⚙️ What Is Tirzepatide? A Dual-Action Research Compound for Metabolic Pathway Studies
Share
What Is Tirzepatide?
Tirzepatide is a synthetic research compound studied for its unique ability to target two metabolic receptors simultaneously:
- GIP receptor (glucose-dependent insulinotropic polypeptide)
- GLP‑1 receptor (glucagon-like peptide-1)
This dual receptor activity makes Tirzepatide a compound of interest in metabolic research focused on glucose regulation, energy balance, and appetite-related hormone signaling.
Explore Tirzepatide at NovaGene Labs →
Why Are Researchers Studying Tirzepatide?
In preclinical and molecular studies, Tirzepatide is evaluated for its potential role in:
- Glucose metabolism and insulin sensitivity
- Hormonal pathways involving the pancreas and brain
- Energy expenditure and appetite signaling
- Dual agonism receptor research models
- Fat metabolism and caloric efficiency
Its structure allows it to interact with two receptors that naturally respond to gut-derived hormones, making it especially valuable for studies around metabolic efficiency and nutrient response.
How Tirzepatide Functions in Research
Tirzepatide is known as a GIP/GLP‑1 receptor agonist, meaning it mimics the activity of two key hormones involved in nutrient sensing:
- GLP‑1R: Known for its role in insulin secretion, slowing digestion, and reducing appetite
- GIPR: Studied for its effects on insulin response and fat metabolism after eating
Tirzepatide binds to both of these receptors, triggering downstream signaling pathways that are actively explored in cell-based assays and endocrine function models.
Why Choose NovaGene Labs?
NovaGene Labs offers high-quality Tirzepatide for researchers investigating dual-receptor mechanisms and metabolic signaling.
- Manufactured under strict quality conditions
- Available in lyophilized and pre-mixed formats
- Cold-shipped only when pre-mixed (lyophilized products are not shipped cold)
- Clearly labeled and intended for Research Use Only
View Tirzepatide Research Compound →
📚 References
- Coskun, T. et al. (2018). Tirzepatide, a dual GIP and GLP-1 receptor agonist: A new class of metabolic hormone analogs. Cell Metabolism, 27(5), 1091–1103.
- Frias, J. P. et al. (2020). Dual agonism in metabolic hormone receptors: Clinical implications and mechanisms. The Lancet Diabetes & Endocrinology, 8(11), 951–963.
- Finan, B. et al. (2013). Multifunctional peptide therapeutics for metabolic research. Nature Reviews Drug Discovery, 12, 267–286.